e-learning
resources
Munich 2014
Sunday, 07.09.2014
Improving diagnosis of thoracic tumours
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cytology sample from EBUS-TBNA for multi-gene analysis in non-small-cell lung cancer (NSCLC)
C. Centeno Clemente, J. Sanz-Santos, F. Andreo, E. Carcereny, T. Moran, E. Castellà, M. Llatjòs, A. M. Muñoz-Mármol, J. L. Ramírez, R. Rosell, J. Ruiz-Manzano (Badalona, Spain)
Source:
International Congress 2014 – Improving diagnosis of thoracic tumours
Session:
Improving diagnosis of thoracic tumours
Session type:
Poster Discussion
Number:
336
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Centeno Clemente, J. Sanz-Santos, F. Andreo, E. Carcereny, T. Moran, E. Castellà, M. Llatjòs, A. M. Muñoz-Mármol, J. L. Ramírez, R. Rosell, J. Ruiz-Manzano (Badalona, Spain). Cytology sample from EBUS-TBNA for multi-gene analysis in non-small-cell lung cancer (NSCLC). Eur Respir J 2014; 44: Suppl. 58, 336
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Comparing performance and cost of EBUS-TBNA versus other methods for diagnosis and staging of non-small cell lung cancer (NSCLC)
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Methilation status in EBUS-NA samples of lung cancer
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Integrative analysis of DNA copy number in metastatic NSCLC identifies drug sensitivity to Afatinib
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Metabolomic analysis of serum samples from patients with lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Brain metastatic recurrence following radically treated lung cancer; a retrospective analysis
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS
Source: International Congress 2016 – Endosonography: EBUS/EUS (B)
Year: 2016
Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Second primary lung cancer in squamous NSCLC patients: The Nancy Biobank's database
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Prognostic value of EGFR mutation in NSCLC in surgical stage
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Breast metastasis from primary EGFR-mutated lung carcinoma or primary tumor?
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013
Symptom-to-treatment intervals in lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Methylation of p16 in EBUS-TBNA samples as a predictor of advanced disease in lung cancer
Source: Annual Congress 2013 –Genetics and genomics of lung disease
Year: 2013
Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC)
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
EBUS-TBNA for nodal restaging and relapse in lung cancer
Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours
Year: 2014
The value of miR221 and miR222 as a biomarker in non small cell lung cancer
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Functional impairment of NK cells in non-small-cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Development and validation of a prognostic index for survival in patients with non-small-cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Prognostic value of preoperative C-reactive protein in resectable non-small cell lung cancer - 5-years prospective study
Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept